🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

86+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 20 of 86 recruiting trials for “juvenile-myasthenia-gravis

Phase 2, PHASE3RecruitingNCT06055959

A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

👨‍⚕️ UCB Cares, 001 844 599 2273📍 9 sites📅 Started Oct 2024View details ↗
Phase 3Enrolling by InvitationNCT06540144

An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis

👨‍⚕️ UCB Cares, 001 844 599 2273📍 10 sites📅 Started Oct 2024View details ↗
NARecruitingNCT06491238

Light vs. Moderate Intensity Exercise in Individuals With Myasthenia Gravis

🏥 HealthPartners Institute📍 1 site📅 Started Sep 2024View details ↗
Phase 2, PHASE3RecruitingNCT06193889

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

👨‍⚕️ MD, Kyverna Therapeutics, Inc.📍 14 sites📅 Started Aug 2024View details ↗
RecruitingNCT06064461

Vitaccess Real MG Registry

👨‍⚕️ Mark JW Larkin, PhD, Vitaccess Ltd📍 8 sites📅 Started Jul 2024View details ↗
Phase 3RecruitingNCT06517758

A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.

🏥 Novartis Pharmaceuticals📍 110 sites📅 Started Jul 2024View details ↗
Phase 3RecruitingNCT06456580

A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)

🏥 Vor Biopharma📍 84 sites📅 Started Jul 2024View details ↗
Phase 1RecruitingNCT06371040

Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis

🏥 Ting Chang, MD📍 1 site📅 Started Jul 2024View details ↗
RecruitingNCT06685055

Markers of Favorable Response to FcRn Inhibitors(INFORM)

👨‍⚕️ Raffaele Iorio, Fondazione Policlinico Universitario A. Gemelli, IRCCS📍 1 site📅 Started Jul 2024View details ↗
Phase 2, PHASE3RecruitingNCT06447597

A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.

🏥 Shanghai Jiaolian Drug Research and Development Co., Ltd📍 18 sites📅 Started Jul 2024View details ↗
Phase 2, PHASE3RecruitingNCT06392386

A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis

🏥 argenx📍 20 sites📅 Started Jun 2024View details ↗
Phase 3RecruitingNCT06463587

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

👨‍⚕️ Medical Responsible, EMD Serono Research & Development Institute, Inc.📍 132 sites📅 Started Jun 2024View details ↗
Phase 2, PHASE3RecruitingNCT06149559

A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis

👨‍⚕️ UCB Cares, 001 844 599 2273📍 13 sites📅 Started Jun 2024View details ↗
RecruitingNCT06455709

Markers of Favorable Response to Complement Inhibitors Therapy

👨‍⚕️ Raffaele Iorio, Fondazione Policlinico Universitario A. Gemelli, IRCCS📍 1 site📅 Started Jun 2024View details ↗
Phase 1, PHASE2RecruitingNCT06106672

Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis

👨‍⚕️ Roy First, MD, COUR Pharmaceutical📍 17 sites📅 Started May 2024View details ↗
Phase 2RecruitingNCT06414954

Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis

🏥 NMD Pharma A/S📍 39 sites📅 Started May 2024View details ↗
RecruitingNCT06441825

Patient Observation With Environmental and Wearable Sensors in Myasthenia Gravis

🏥 Heinrich-Heine University, Duesseldorf📍 1 site📅 Started May 2024View details ↗
Phase 1RecruitingNCT06220201

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

👨‍⚕️ Bristol-Myers Squibb, Bristol-Myers Squibb📍 35 sites📅 Started Mar 2024View details ↗
RecruitingNCT06241521

Myasthenia Gravis Registry in China

🏥 Huashan Hospital📍 16 sites📅 Started Feb 2024View details ↗
RecruitingNCT04535843

Precision Diagnosis and Prospective Cohort Study for Myasthenia Gravis: Multicenter Analysis in China

👨‍⚕️ Chongbo Zhao, MD, Huashan Hospital, Shanghai,China📍 4 sites📅 Started Feb 2024View details ↗
← PreviousPage 3 of 5Next →

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →